Literature DB >> 30874767

The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer.

Darcie D Seachrist1, Ruth A Keri1,2,3.   

Abstract

Activins and inhibins are closely related protein heterodimers with a similar tissue distribution; however, these two complexes have opposing functions in development and disease. Both are secreted cytokine hormones, with activin the primary inducer of downstream signaling cascades and inhibin acting as a rheostat that exquisitely governs activin function. Adding to the complexity of activin signaling, follistatin, a highly glycosylated monomeric protein, binds activin with high affinity and restrains downstream pathway activation but through a mechanism distinct from that of inhibin. These three proteins were first identified as key ovarian hormones in the pituitary-gonadal axis that direct the synthesis and secretion of FSH from the pituitary, hence controlling folliculogenesis. Research during the past 30 years has expanded the roles of these proteins, first by discovering the ubiquitous expression of the trio and then by implicating them in a wide array of biological functions. In concert, these three hormones govern tissue development, homeostasis, and disease in multiple organ systems through diverse autocrine and paracrine mechanisms. In the present study, we have reviewed the actions of activin and its biological inhibitors, inhibin, and follistatin, in mammary gland morphogenesis and cancer.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30874767      PMCID: PMC6475112          DOI: 10.1210/en.2019-00015

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  94 in total

1.  The type II activin receptors are essential for egg cylinder growth, gastrulation, and rostral head development in mice.

Authors:  J Song; S P Oh; H Schrewe; M Nomura; H Lei; M Okano; T Gridley; E Li
Journal:  Dev Biol       Date:  1999-09-01       Impact factor: 3.582

2.  The activin A-follistatin system: potent regulator of human extracellular matrix mineralization.

Authors:  Marco Eijken; Sigrid Swagemakers; Marijke Koedam; Cobie Steenbergen; Pieter Derkx; André G Uitterlinden; Peter J van der Spek; Jenny A Visser; Frank H de Jong; Huibert A P Pols; Johannes P T M van Leeuwen
Journal:  FASEB J       Date:  2007-04-20       Impact factor: 5.191

3.  Development of novel activin-targeted therapeutics.

Authors:  Justin L Chen; Kelly L Walton; Sara L Al-Musawi; Emily K Kelly; Hongwei Qian; Mylinh La; Louis Lu; George Lovrecz; Mark Ziemann; Ross Lazarus; Assam El-Osta; Paul Gregorevic; Craig A Harrison
Journal:  Mol Ther       Date:  2014-11-17       Impact factor: 11.454

4.  Induction of prostanoid, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A.

Authors:  R M Nüsing; J Barsig
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition.

Authors:  Ulrich Valcourt; Marcin Kowanetz; Hideki Niimi; Carl-Henrik Heldin; Aristidis Moustakas
Journal:  Mol Biol Cell       Date:  2005-02-02       Impact factor: 4.138

6.  Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival.

Authors:  Catherine Zabkiewicz; Jeyna Resaul; Rachel Hargest; Wen Guo Jiang; Lin Ye
Journal:  Cancer Genomics Proteomics       Date:  2017 Jul-Aug       Impact factor: 4.069

7.  Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer.

Authors:  Jacqueline S Jeruss; Charles D Sturgis; Alfred W Rademaker; Teresa K Woodruff
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

8.  Localization of activin and inhibin subunits, receptors and SMADs in the mouse mammary gland.

Authors:  Jacqueline S Jeruss; Jose Y Santiago; Teresa K Woodruff
Journal:  Mol Cell Endocrinol       Date:  2003-05-30       Impact factor: 4.102

Review 9.  Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer.

Authors:  Kimberly M Arnold; Lynn M Opdenaker; Daniel Flynn; Jennifer Sims-Mourtada
Journal:  Cancer Growth Metastasis       Date:  2015-01-29

10.  Activin signaling as an emerging target for therapeutic interventions.

Authors:  Kunihiro Tsuchida; Masashi Nakatani; Keisuke Hitachi; Akiyoshi Uezumi; Yoshihide Sunada; Hiroshi Ageta; Kaoru Inokuchi
Journal:  Cell Commun Signal       Date:  2009-06-18       Impact factor: 5.712

View more
  2 in total

Review 1.  Endometriosis and polycystic ovary syndrome are diametric disorders.

Authors:  Natalie L Dinsdale; Bernard J Crespi
Journal:  Evol Appl       Date:  2021-05-14       Impact factor: 4.929

2.  ZMIZ2 promotes the development of triple-receptor negative breast cancer.

Authors:  Xiaopan Zou; Yan Liu; Jun Di; Wei Wei; Nobumoto Watanabe; Jiang Li; Xiaomeng Li
Journal:  Cancer Cell Int       Date:  2022-01-31       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.